marked.bio

PARP1-selective inhibitor (brain-penetrant) · small molecule

AZD9574

1 active trials across 3 of our biomarkers, targeting PARP1. Not approved for any biomarker on marked.bio yet.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
BRCA1/2 mutation 1 1 Phase 1/2
HER2-low / ultralow (IHC 1+ or 2+/ISH-) 1 1 Phase 1/2
IDH1/2 mutation 1 1 Phase 1/2

Sponsors

Industry sponsors leading active biomarker-selected trials of AZD9574.

  1. AstraZeneca 1

Trials

1 of 1 trials shown

  1. Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

    Recruiting Phase 1/2 AstraZeneca Started 2022Primary completion 2028-02 NCT05417594

    AZD9574temozolomide[11C]AZ1419 3391trastuzumab deruxtecandatopotamab deruxtecan

    …ced or metastatic disease and evidence of a predicted loss of function germline or tumour mutation in BRCA1, BRCA2, PALB2, RAD51C, or RAD51D,

    BRCA1/2 mutationIDH1/2 mutationHER2-low / ultralow (IHC 1+ or 2+/ISH-)Advanced Solid Malignancies